immunobodyr

  1. T

    Scancell Enters Research Collaboration With Immatics To Develop Novel ImmunoBody(R) V

    Scancell Holdings Plc, (PLUS:SCLP), the developer of therapeutic cancer vaccines, announces a research collaboration with immatics biotechnologies GmbH ("immatics") to explore the development of novel ImmunoBody® vaccines for colorectal cancer. Immatics discovers and develops tumor-associated...
Back
Top